Include Payers in Your Product Development and Clinical Use Processes

Area of Science:

• Medical device development
• Healthcare economics
• Wound management

Background:

• Food and Drug Administration (FDA) clearance or approval for medical devices does not ensure reimbursement.
• Reimbursement, particularly coverage decisions by payers, is often overlooked until after regulatory approval.
• Lack of payer coverage can prevent the adoption and use of innovative wound care technologies.

Discussion:

• This article highlights two new Medicare coverage processes designed to address reimbursement gaps.
• It emphasizes the need for proactive engagement with payers regarding the value of medical devices for wound and ulcer management.
• Stakeholders must advocate for coverage to ensure patient access to necessary treatments.

Key Insights:

• FDA approval is a necessary but insufficient condition for medical device market success.
• Payer coverage decisions significantly impact the accessibility and utilization of medical devices in clinical practice.
• Early and continuous communication with payers is vital for securing reimbursement.

Outlook:

• The described Medicare processes aim to integrate coverage considerations earlier in the device lifecycle.
• Increased payer education can lead to better patient outcomes by facilitating access to advanced wound care solutions.
• Future strategies should focus on demonstrating clinical and economic value to payers to ensure sustained reimbursement.